According World Health Organization 2024 Global Hepatitis Report number life lost due viral hepatitis increasing disease second leading infectious cause death globally -- 1.3 million death per year tuberculosis top infectious killer.The report released World Hepatitis Summit highlight despite better tool diagnosis treatment decreasing product price testing treatment coverage rate stalled reaching elimination goal 2030 still achievable swift action taken now.New data 187 country show estimated number death viral hepatitis increased 1.1 million 2019 1.3 million 2022 83 caused hepatitis B 17 hepatitis C. Every day 3500 people dying globally due hepatitis B C infections. “ report paint troubling picture despite progress globally preventing hepatitis infection death rising far people hepatitis diagnosed treated ” said Director-General Dr Tedros Adhanom Ghebreyesus “ committed supporting country use tool disposal access price save life turn trend around. ” Updated estimate indicate 254 million people live hepatitis B 50 million hepatitis C 2022 Half burden chronic hepatitis B C infection among people 30–54 year old 12 among child 18 year age Men account 58 cases.New incidence estimate indicate slight decrease compared 2019 overall incidence viral hepatitis remains high 2022 2.2 million new infection 2.5 million 2019 include 1.2 million new hepatitis B infection nearly 1 million new hepatitis C infection 6000 people getting newly infected viral hepatitis day.The revised estimate derived enhanced data national prevalence survey also indicate prevention measure immunization safe injection along expansion hepatitis C treatment contributed reducing incidence Global progress gap diagnosis treatmentAcross region 13 people living chronic hepatitis B infection diagnosed approximately 3 7 million received antiviral therapy end 2022 Regarding hepatitis C 36 diagnosed 20 12.5 million received curative treatment.These result fall well global target treat 80 people living chronic hepatitis B hepatitis C 2030 However indicate slight consistent improvement diagnosis treatment coverage since last reported estimate 2019 Specifically hepatitis B diagnosis increased 10 13 treatment 2 3 hepatitis C diagnosis 21 36 treatment 13 20 .The burden viral hepatitis varies regionally African Region bear 63 new hepatitis B infection yet despite burden 18 newborn region receive hepatitis B birth-dose vaccination Western Pacific Region account 47 hepatitis B death treatment coverage stand 23 among people diagnosed far low reduce mortality Bangladesh China Ethiopia India Indonesia Nigeria Pakistan Philippines Russian Federation Viet Nam collectively shoulder nearly two-thirds global burden hepatitis B C. Achieving universal access prevention diagnosis treatment ten country 2025 alongside intensified effort African Region essential get global response back track meet Sustainable Development Goals.Disparities pricing service deliveryDespite availability affordable generic viral hepatitis medicine many country fail procure lower prices.Pricing disparity persist across within region many country paying global benchmark even off-patent drug included voluntary licensing agreement example although tenofovir treatment hepatitis B patent available global benchmark price US 2.4 per month 7 26 reporting country paid price benchmark Similarly 12-week course pangenotypic sofosbuvir/daclatasvir treat hepatitis C available global benchmark price US 60 yet 4 24 reporting country paid price benchmark.Service delivery remains centralized vertical many affected population still face out-of-pocket expense viral hepatitis service 60 reporting country offer viral hepatitis testing treatment service free charge either entirely partially public sector Financial protection lower African Region one third reporting country provide service free charge.Recommendations accelerating hepatitis eliminationThe report outline series action advance public health approach viral hepatitis designed accelerate progress towards ending epidemic 2030 include expanding access testing diagnostics shifting policy implementation equitable treatment strengthening primary care prevention effort simplifying service delivery optimizing product regulation supply developing investment case priority country mobilizing innovative financing using improved data action andengaging affected community civil society advancing research improved diagnostics potential cure hepatitis B Funding remains challengeFunding viral hepatitis global level within dedicated country health budget sufficient meet need arises combination factor including limited awareness cost-saving intervention tool well competing priority global health agenda report seek shed light strategy country address inequity access tool affordable price available